Skip to main content
2025 IDWeek Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
Live Streamed
On Demand
On Demand

V3. Studies of treatment and prevention of viral infections

Poster Session: Virology

(P-2195) Influence of Nucleos(t)ide Analogue Use with Bulevirtide on Treatment Outcomes in Chronic Hepatitis Delta

Wednesday, October 22, 2025
12:15 PM - 1:30 PM US ET
Location: Poster Hall B4-B5

    Co-Author(s)

  • PL

    Pietro Lampertico, MD

    CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan
    Milan, Lombardia, Italy

    • Co-Author(s)

  • MB

    Maurizia Brunetto, MD

    Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
    Pisa, Toscana, Italy

  • MB

    Maria Buti, MD, PhD

    Hospital Universitario Vall d’Hebron, Barcelona, Spain; CIBEREHD del Instituto Carlos III, Madrid, Spain
    Barcelona, Catalonia, Spain

  • SA

    Soo Aleman, MD, PhD

    Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden
    Stockholm, Sodermanlands Lan, Sweden

  • Pavel Bogomolov, MD, Ph.D (he/him/his)

    Head of hepatology dept.
    M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
    Moscow, Moskva, Russia

  • VC

    Vladimir Chulanov, MD, PhD

    Sechenov University
    Moscow, Moskva, Russia

  • NM

    Nina Mamonova, MD

    FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
    Moscow, Moskva, Russia

  • VM

    Viacheslav Morozov, MD, PhD

    LLC Medical Company Hepatolog, Samara, Russian Federation
    Samara, Samara, Russia

  • OS

    Olga Sagalova, MD, PhD

    South Ural State Medical University, Chelyabinsk, Russian Federation
    Chelyabinsk, Moskva, Russia

  • TS

    Tatiana Stepanova, MD

    LLC Clinic of Modern Medicine, Moscow, Russian Federation
    Moscow, Moskva, Russia

    • Presenting Author(s)

  • Renee-Claude Mercier, PharmD (she/her/hers)

    Director, Clinical Development
    Gilead Sciences, Inc.
    Foster City, CA, United States

    • Co-Author(s)

  • ML

    Mingyang Li, PhD

    Gilead Sciences, Inc.
    Foster City, California, United States

  • AL

    Amos Lichtman, MPH, MD

    Gilead Sciences, Inc.
    Foster City, California, United States

  • Dmitry Manuilov, MD

    Sr. Director, Virology Clinical Development
    Gilead Sciences, Inc.
    Foster City, California, United States

  • HW

    Heiner Wedemeyer, MD

    Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany
    Hannover, Sachsen, Germany

  • Tarik Asselah, MD PhD (he/him/his)

    Professor of Hepatology, Head of Viral Hepatitis
    Université de Paris-Cité. Hôpital Beaujon, Paris, France., France

  • FZ

    Fabien Zoulim, MD, PhD

    Hospital Croix Rousse
    Lyon, Rhone-Alpes, France